SecBot SecBot

ALMR

Alamar Biosciences, Inc.
Nasdaq· CIK 0002104204 Biotech & Drug Discovery
$30.69 +0.97 (+3.26%)
Oct 23 4:00 PM ET · prev $29.72
Market cap
$2.1B
Mid cap
Consensus
Buy
82% Buy or better · 11 analysts
Median target
🔒 Subscribers only
Since first trade
+39.5%
from $22.00 · Apr 17
30 days
−7.6%
from $33.20
Range since listing
$19.09–38.13
−20% from high · low May 26
Avg volume 20D
794.9K
shares / day
Short interest
2.81M
≈4.0% of shares · +32.5%
Days to cover
4.3
at average volume
Insider net
-$17.9M
0 buyers · 1 seller · since Oct 15
New fund stakes
10
Q2 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 2 bearish · 2 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/7 ·Next Earnings date, Nov 3, 2026
Strongest BEARISH Qiming Venture Partners VI, L.P., a major venture backer of Alamar Biosciences, filed a Form 144 notice of…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $17.9M.

  • InstitutionsBULLISH

    Q2 2026: 10 added (10 new), 0 trimmed or exited. Largest new: Ark Investment Management $37.2M, Alliancebernstein $27.2M.

  • AnalystsBULLISH

    9 of 11 rate it Buy or better.

  • Short sellersBUILDING

    Short interest +32.5% to 2.81M shares. 4.3 days to cover, ≈4.0% of shares.

  • TrendDOWNTREND

    0% below its 50-day average.

Who's buying

13F· Q2 2026
10
new positions
0
exits
$200.5M
in new stakes
FundMoveSharesValue
ARK Investment Management LLCNEW1,373,959$37.2M
ALLIANCEBERNSTEIN L.P.NEW1,003,077$27.2M
BlackRock, Inc.NEW911,445$24.7M
MILLENNIUM MANAGEMENT LLCNEW865,764$23.5M
FMR LLCNEW829,424$22.5M
Artisan Partners Limited PartnershipNEW613,744$16.6M
VANGUARD CAPITAL MANAGEMENT LLCNEW463,385$12.6M
FARALLON CAPITAL MANAGEMENT, L.L.C.NEW462,900$12.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 82% rate it Buy or better
Strong Buy4Buy5Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 11, 2026Stifel
MAINTAIN
MAINTAINBuy
Aug 11, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
May 12, 2026Leerink Partners
INITIATE
INITIATEOutperform
May 12, 2026TD Cowen
INITIATE
INITIATEBuy
May 12, 2026JP Morgan
INITIATE
INITIATEOverweight
May 12, 2026Stifel
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$17.9M
sold · 1 insider
DateInsiderTypeValue
Oct 22, 2026
Qiming Corporate GP VI, Ltd.
10%+ Owner
SELL$3.1K
Oct 22, 2026
Qiming Corporate GP VI, Ltd.
10%+ Owner
SELL$1.3M
Oct 22, 2026
Qiming Corporate GP VI, Ltd.
10%+ Owner
SELL$113.5K
Oct 22, 2026
Qiming Corporate GP VI, Ltd.
10%+ Owner
SELL$36.1K
Oct 22, 2026
Qiming Corporate GP VI, Ltd.
10%+ Owner
SELL$313.2K
Oct 22, 2026
Qiming Corporate GP VI, Ltd.
10%+ Owner
SELL$375.0K
Oct 22, 2026
Qiming Corporate GP VI, Ltd.
10%+ Owner
SELL$29.4K
Oct 22, 2026
Qiming Corporate GP VI, Ltd.
10%+ Owner
SELL$255.1K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
2,810,938
shares short
+32.5%
vs prior settlement
4.3
days to cover
≈4.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Insider
Qiming Corporate GP VI, Ltd. sold 99 shares
10%+ Owner @ $30.81 ($3.1K)
Oct 22, 2026 Insider
Qiming Corporate GP VI, Ltd. sold 46,290 shares
10%+ Owner @ $29.00 ($1.3M)
Oct 22, 2026 Insider
Qiming Corporate GP VI, Ltd. sold 3,683 shares
10%+ Owner @ $30.81 ($113.5K)
Oct 15, 2026 SEC
Qiming Venture Partners VIII-HC, L.P., a venture capital affiliate of Alamar Biosciences, has filed a Form 144 notice…
144 — Impact 5/10
Oct 15, 2026 SEC
Qiming Venture Partners VI, L.P., a major venture backer of Alamar Biosciences, filed a Form 144 notice of intent to…
144 — Impact 6/10
Oct 15, 2026 SEC
Qiming Managing Directors Fund VI, L.P., a pre-IPO venture investor in Alamar Biosciences, filed a Form 144 on October…
144 — Impact 2/10
Oct 5, 2026 Press
Alamar Biosciences announced the appointment of Bob Ragusa (former CEO of GRAIL and COO of Illumina) to its board of…
Impact 2/10
Oct 5, 2026 Leadership
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Oct 5, 2026
Leadership
Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
Strengthens leadership team with appointments of John Brottem as general counsel and Amelia Merrill as chief people officer Strengthens leadership…
Sep 30, 2026
Short interest
Short Interest: ALMR up 32% to 2.8M shares
Settlement 2026-09-30 | Days to cover: 4.25 | ≈4.05% of shares outstanding (est.)
Sep 24, 2026
FDA
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab Blood…
Sep 1, 2026
Press release
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling…
Aug 10, 2026
Contract
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
Expanded collaboration applies multiplex protein profiling across 86,000 additional samples, enabling researchers to move beyond single biomarkers…

SecBot reports

20 filings · 4 press releases · 11 bullish · 2 bearish · 7 neutral
All ALMR filing & press-release reports (24)